Results 141 to 150 of about 116,067 (241)

Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. [PDF]

J Immunother Cancer, 2021
Dalla Pietà A, Cappuzzello E, Palmerini P, Ventura A, Visentin A, Astori G, Chieregato K, Mozzo V, Perbellini O, Tisi MC, Trentin L, Visco C, Ruggeri M, Sommaggio R, Rosato A.   +14 more
europepmc   +1 more source

Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways

Advanced Science, EarlyView.
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo, Hansen Lin, Haoqian Feng, Lei Tan, Xi Liu, Yong Huang, Junjie Cen, Jiajie Chen, Xinwei Zhou, Mingjie Lin, Wuyuan Liao, Zheyu Ai, Minyu Chen, Yinghan Wang, Wei Chen, Junhang Luo, Yanping Liang   +16 more
wiley   +1 more source

Safety and efficacy of cytokine-induced killer cells for gastric cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Zhu M, Yang C, Liang B, Liu Q.
europepmc   +1 more source

NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation. [PDF]

Front Immunol, 2021
Wu X, Sharma A, Oldenburg J, Weiher H, Essler M, Skowasch D, Schmidt-Wolf IGH.   +6 more
europepmc   +1 more source

NIR‐II Light‐Triggered Electron Flow Initiates Cuproptosis‐Centered Thermoelectric‐Immunotherapy for Breast Cancer

Advanced Science, EarlyView.
A NIR‐II light‐activatable thermoelectric nanoreactor converts surface‐bound Cu2+ into bioactive Cu+ via directed electron flow. This spatiotemporally controlled reduction triggers potent cuproptosis and immunogenic cell death, eradicating primary tumors and, together with aPD‐1 therapy, suppressing metastases while establishing durable immune memory ...
Boyu Yuan, Qin Fan, Shushu Chu, Shining Yang, Yuechao Yang, Chenxi Zhang, Jinqiao Zhang, Xinran Qu, Yiju Wei, Xin Wang, Ziliang Dong   +10 more
wiley   +1 more source

First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia. [PDF]

J Clin Oncol
Rettinger E, Heckl D, Hutter M, Salzmann-Manrique E, Luedtke M, Huenecke S, Bremm M, Cappel C, Bug G, Greil J, Meisel R, Wagner-Drouet EM, Serve H, Güngör T, Klusmann JH, Klingebiel T, Bader P, Bonig H.   +17 more
europepmc   +1 more source

Efficacy of Enhanced Cytokine-Induced Killer Cells as an Adjuvant Immunotherapy for Renal Cell Carcinoma: Preclinical and Clinical Studies. [PDF]

J Healthc Eng, 2021
Yang Y, Wang RQ, Zhong YM, Meng MY, Zhao YY, Yang LR, Li L, Hou ZL.   +7 more
europepmc   +1 more source

Therapeutic Dendritic Cells/Cytokine-induced Killer Cells [PDF]

, 2020
openaire   +1 more source

A Pancreatitis‐Inspired Trypsinogen Nanoplatform Reprograms Tumor‐Associated Macrophages via NF‐κB for Pancreatic Cancer Immunotherapy

Advanced Science, EarlyView.
Trypsinogen‐loaded nanoparticles reprogram TAMs via NF‐κB/NLRP3, driving M2→M1 conversion and potent phagocytosis to unleash antitumor immunity. ABSTRACT Although reprogramming tumor‐associated macrophages (TAMs) represents a promising therapeutic strategy, approaches that are both precise and safe remain scarce.
Lei Cao, Yu He, Wenhao Li, Bo Gong, Han Lin, Jianlin Shi, Yuan Yong, Wencheng Wu   +7 more
wiley   +1 more source

Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma. [PDF]

Sci Rep
Li S, Qin J, Sun Q, Zhao H, Xiong Y, Wang Y, Han Y, Zhang J, Zhang W, Shen M, Yang F, Ren B, Zhou L, Li R, Hui Z, Tian X, Cao S, Du W, Yu W, Liu L, Zhang X, Ren X.   +21 more
europepmc   +1 more source